Compare Five Below Inc (FIVE) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs 10X Genomics Inc — how do they compare? Five Below Inc trades at $209.72 (market cap $11.25B), while 10X Genomics Inc trades at $79.44 (market cap $9.92B). The key difference: Five Below Inc and 10X Genomics Inc are close in size by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and 10X Genomics Inc for 92 Days on average.
| FIVE | TXG | |
|---|---|---|
Market Cap | $11.25B | $9.92B |
Volume | 986,546 | 9,372,166 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $97.74 |
52-Week Low | $138.49 | $11.48 |
Typical Hold Time | 46 Days | 92 Days |
Enterprise Value | $12.10B | $9.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $209.56, down 0.17% on the day, with a bearish technical signal despite bullish oscillators. The company shows strong profitability with 40.26% gross margins and 28.25% ROE, though net margins declined to 6.54% in 2025. Recent earnings beats and a raised 2026 outlook highlight growth momentum, supported by store expansion and digital initiatives. Cash flow improved significantly in 2025 with $152M net inflow after two years of negative flows.
The stock offers substantial upside to the $298.44 consensus target, with 60% analyst buy ratings and no sell recommendations. Key risks include premium valuation (P/E 18.32) and execution pressure amid consumer spending concerns. Growth catalysts include the $600M buyback and store revamp strategy, though technical resistance near $212 may limit near-term gains.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
